---
title: "Vyome Stock (HIND) Rockets on Uveitis Study Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257743400.md"
description: "Vyome's stock surged 61.12% in pre-market trading after announcing that its drug VT-1908 is as effective as steroids for treating anterior uveitis, a common eye condition. This finding could position Vyome to capture a share of the projected $20 billion uveitis market by 2030. Despite today's gains, the stock has seen a year-to-date decline of 98.64% and a 99.33% drop over the past year, with heavy trading volume of 8.5 million shares compared to the average of 547,000."
datetime: "2025-09-17T12:54:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257743400.md)
  - [en](https://longbridge.com/en/news/257743400.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257743400.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/257743400.md) | [繁體中文](https://longbridge.com/zh-HK/news/257743400.md)


# Vyome Stock (HIND) Rockets on Uveitis Study Data

Vyome noted in its data that VT-1908 was as effective as steroids at treating anterior uveitis, which is the most common form of uveitis. This is important as steroids can cause problems when used to treat uveitis, such as cataracts and glaucoma. With these latest study results, Vyome has the potential to tap into a market that is expected to reach $20 billion by 2030.

Dr. Shiladitya Sengupta, co-founder of Vyome and Associate Professor of Medicine at Harvard Medical School, said, "Inflammation is one of the biggest problems of our time, which is often linked to the immune system, and we are addressing the root cause in tangible and specific applications in the eye. The fact that VT-1908 is as effective as a steroid is exciting as we can aim to replace steroids in the eye, which are associated with a number of complications."

## **Vyome Stock Movement Today**

Vyome stock was up 61.12% in pre-market trading on Wednesday, following a 6.28% fall yesterday. The shares have also decreased 98.64% year-to-date and 99.33% over the past 12 months. Today's news came with heavy trading, as some 8.5 million shares changed hands, compared to a three-month daily average of about 547,000 units.

### Related Stocks

- [Vyome Holdings, Inc. (HIND.US)](https://longbridge.com/en/quote/HIND.US.md)

## Related News & Research

- [Sentynl and PRG partner for Progerinin licence](https://longbridge.com/en/news/279414537.md)
- [Here's How Much $100 Invested In abrdn Physical Silver Shares ETF 10 Years Ago Would Be Worth Today](https://longbridge.com/en/news/281394387.md)
- [Destiny Tech100 Stock Rises After SpaceX IPO Rumors](https://longbridge.com/en/news/281415250.md)
- [BREAKINGVIEWS-SpaceX IPO will gauge market moxie more than depth](https://longbridge.com/en/news/281406751.md)
- [Fired via email? Some of the 30,000 workers cut by Oracle woke up to a morning message saying they were laid off.](https://longbridge.com/en/news/281429821.md)